A Soluble Chimeric Complement Inhibitory Protein That Possesses Both Decay-Accelerating and Factor I Cofactor Activities

Journal of Immunology

Volumn 158, Issue 6, 1997, Pages 2872-2881

  Higgins, Paul J ^a   Ko, Jone Long ^a,b   Lobell, Robert ^a   Sardonini, Charles ^a   Alessi, Mary Kay ^a   Yeh, C Grace ^a  

^a CytoMed Inc   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT INHIBITOR; DECAY ACCELERATING FACTOR; HYBRID PROTEIN; LEUKOCYTE ANTIGEN; MCP PROTEIN, RAT; MEMBRANE COFACTOR PROTEIN; MEMBRANE PROTEIN;

ANAPHYLAXIS; ANIMAL; ARTICLE; BIOSYNTHESIS; COMPLEMENT ACTIVATION; DRUG EFFECT; FEMALE; GENETICS; GUINEA PIG; ISOLATION AND PURIFICATION; PHYSIOLOGY; PROTEIN ENGINEERING; RAT; RAT STRAIN; SOLUBILITY;

ANAPHYLAXIS; ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; FEMALE; GUINEA PIGS; MEMBRANE GLYCOPROTEINS; PROTEIN ENGINEERING; RATS; RATS, INBRED STRAINS; RECOMBINANT FUSION PROTEINS; SOLUBILITY;

EID: 0031569285     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Frank, M., and L. Fries. 1989. Complement. In Fundamental Immunology. W. Paul, ed. Raven Press, New York, p. 679.
2. Lindsay, T., B. Rubin, A. Romaschin, and A. Walker. 1994. Complement activation. In Ischemia-Reperfusion Injury of Skeletal Muscle. G. Fantini, ed. R. G. Landes Co., New York, p. 77.
3. Negoro, N., M. Okamura, T. Takeda, S. Koda, K. Amatsu, T. Inoue, J. Curd, and Y. Kanayama. 1989. The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus. Arthritis Rheum. 32: 1233.
4. Earis, J., E. Marcuson, and A. Bernstein. 1985. Complement activation after myocardial infarction. Chest 87:186.
5. Davis, C., F. Moore, M. Rodrick, D. Fearon, and J. Mannick. 1987. Neutrophil activation after burn injury: contribution of the classic complement pathway and of endotoxin. Surgery 102:477.
6. Hack, C., J. Nuijens, R. Felt-Bersma, W. Schreuder, A. Eerenberg-Belmer, J. Paardekooper, W. Bronsveld, and L. Thijs. 1989. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am. J. Med. 86:20.
7. Meade, P., W. Shoemaker, T. Donnelly, E. Abraham, M. Jagels, G. Cryer, T. Hugli, M. Bishop, and C. Wo. 1994. Temporal patterns of hemodynamics, oxygen transport, cytokine activity, and complement activity in the development of adult respiratory distress syndrome after severe injury. J. Trauma 16:651.
8. Hourcade, D., M. Holers, and J. Atkinson. 1989. The regulators of complement activation (RCA) gene cluster. Adv. Immunol. 45:381.
9. Liszewski, M., T. Post, and J. Atkinson. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9:431.
10. Lublin, D., and J. Atkinson. 1989. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7:35.
11. Hsi, B., C. Yeh, P. Fenichel, M. Samson, and C. Grivaux. 1988. Monoclonal antibody GB24 recognizes a trophoblast-lymphocyte cross-reactive antigen. Am. J. Reprod. Immunol. Microbiol. 18:21.
12. Seya, T., J. Turner, and J. Atkinson. 1986. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163:837.
13. Laemmli, U. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.
14. Medof, M., T. Kinoshita, and V. Nussenzweig. 1985. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 160:1558.
15. Chang, Y., and I. Otterness. 1981. Effects of pharmacologic agents on the reversed passive Arthus reaction in the rat. Eur. J. Pharmacol. 69:155.
16. May, J., and M. Frank. 1972. Complement-mediated tissue damage: contribution of the classical and alternative complement pathways in the Forssman reaction. J. Immunol. 108:1517.
17. 2 synthetase inhibitor. Prostaglandins Leuk. Med. 26:133.
18. Maroko, P., C. Carpenter, M. Chiariello, M. Fishbein, P. Radvany, J. Knostman, and S. Hale. 1978. Reduction by cobra venom factor of myocardial necrosis after coronary occlusion. J. Clin. Invest. 61:661.
19. Tavakoli, R., A. Michel, J. Cardoso, E. Ayani, F. Maillet, F. Fontaliran, S. Crougneau, B. Weill, and D. Houssin. 1993. Prolonged survival of guinea pig-to-heart xenografts using repeated low doses of cobra venom factor. Transplant. Proc. 25:407.
20. Fodor, W., B. Williams, L. Matis, J. Madri, S. Rollins, J. Knight, W. Velander, and S. Squinto. 1994. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl. Acad. Sci. USA 91:11153.
21. Iwata, K., T. Seya, H. Ariga, and S. Nagasawa. 1994. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. J. Immunol. 152:3436.
22. Kaneko, I., K. Kamoshida, and S. Takahashi. 1989. Complestatin, a potent anti-complement substance produced by Streptomyces lavendulae. J. Antibiot. 42:236.
23. Issekutz, A., D. Roland, and R. Patrick. 1990. The effect of FUT-175 (nafamstat mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo. Int. J. Immunopharm. 12:1.
24. Miyagawa, S., R. Shirakura, G. Matsumiya, N. Fukushima, S. Nakata, H. Matsuda, M. Matsumoto, H. Kitamura, and T. Seya. 1993. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT-175. Transplantation 55:709.
25. Weiler, J., R. Edens, R. Linhardt, and Kapelanski, D. 1992. Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148:3210.
26. Quigg, R. 1992. Inhibition of the alternative pathway of complement by glomerular chondroitin sulphate proteoglycan. Immunology 76:373.
27. Rinder, C. S., H. M. Rinder, B. R. Smith, J. C. K. Fitch, M. J. Smith, J. B. Tracey, L. A. Matis, S. P. Squinto, and S. A. Rollins. 1995. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation J. Clin. Invest. 1564-1572.
28. Moran, P., H. Beasley, A. Gorrell, E. Martin, P. Gribling, H. Fuchs, N. Gillett, L. Burton, and I. Caras. 1992. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J. Immunol. 149: 1736.
29. Yeh, C. G., H. Marsh, G. Carson, L. Berman, M. Concino, S. Scesney, R. Kuestner, R. Skibbens, K. Donahue, and S. Ip. 1991. Recombinant soluble human complement receptor type I inhibits inflammation in the reversed passive Arthus reaction in rats. J. Immunol. 146:250.
30. Weissman, H., T. Bartow, M. Leppo, H. Marsh, G. Carson, M. Concino, M. Boyle, K. Roux, M. Weisfeldt, and D. Fearon. 1990. Soluble human complement receptor type I: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.